279 B-blockers as a Novel Management of Osteosarcoma: Pros and Cons emerged from an in vivo Experimental Model

280 Increased Neoadjuvant Chemotherapy to Surgery Time Interval is Associated with Decreased Tumor Percent Necrosis in Osteosarcoma

281 Decreased Tumor Percent Necrosis is Associated with Positive Final Margin Status in Osteosarcoma

282 Orthopaedic Oncology Administrative Coding Data Submitted to the U.S. News & World Report: Accuracy and Implications

283 The utility of newly emerging DNA and RNA panel in the diagnosis and treatment of soft tissue sarcomas; Real world data based on nation-wide database